Chester County News and Community Website
EXTON, PA — Lungpacer Medical announced the enrollment of the first six patients in its landmark STARI (STimulation to Activate RespIration) clinical trial, a study evaluating the company’s next-generation AeroNova …
Lungpacer Launches Pivotal STARI Trial to Transform Critical Care Recovery Read More EXTON, PA — Lungpacer Medical Inc. has secured a significant reimbursement boost for its AeroPace® System, with the Centers for Medicare & Medicaid Services (CMS) granting New Technology Add-on Payment …
CMS Grants NTAP Status to Lungpacer’s AeroPace System, Boosting Hospital Reimbursement Read More EXTON, PA — Lungpacer Medical, Inc. has announced pivotal results from the RESCUE-3 trial, published in the American Journal of Respiratory and Critical Care Medicine, showcasing the groundbreaking benefits of …
Lungpacer Medical Publishes Landmark Findings on AeroPace System in Critical Care Read More EXTON, PA — Lungpacer Medical is set to make a significant impact at the ATS 2025 International Conference in San Francisco, where the company will present breakthroughs in interventional therapies …
Lungpacer Medical to Present Innovative Research at ATS 2025 Read More EXTON, PA — Lungpacer Medical has appointed Kevin Kearney as Chief Commercial Officer (CCO), a strategic move aimed at bolstering the company’s growth and market position in the critical care …
Lungpacer Medical Names Kevin Kearney as Chief Commercial Officer Read More EXTON, PA — Lungpacer Medical has announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for the STARI (STimulation to Activate RespIration) clinical trial. …
Lungpacer Medical Secures FDA Approval for AHRF Trial Read More EXTON, PA — Lungpacer Medical has unveiled promising results from its groundbreaking STIMULUS trial, a Phase 1 study conducted in collaboration with Toronto General Hospital. Presented at the 2025 Transcatheter Heart …
Lungpacer Medical Shares Promising Results from STIMULUS Trial Read More EXTON, PA — Lungpacer Medical announced that its AeroPace® System has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA). The approval marks a pivotal moment in …
Lungpacer Medical’s AeroPace System Gains FDA Approval, Transforming Respiratory Care Read More EXTON, PA — Lungpacer Medical has announced that its innovative AeroPace System is currently under review by the Food and Drug Administration (FDA) as part of a premarket approval (PMA) application. …
Lungpacer Medical’s AeroPace System Under FDA Review: A Potential Game-Changer for Ventilated Patients Read More